Biotech Ideas

[gfp927z]

>>> Surface Oncology, Inc. (SURF), a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; SRF388 targeting interleukin 27; SRF813 targeting CD112R; and SRF114 targeting the chemokine receptor CCR8. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and GlaxoSmithKline to develop and commercialize specified antibodies, including SRF813 targeting CD112R. Surface Oncology, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

<<<